In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition

BACKGROUND: Despite great development in genome and proteome high-throughput methods, treatment failure is a critical point in the management of most solid cancers, including breast cancer (BC). Multiple alternative mechanisms upon drug treatment are involved to offset therapeutic effects, eventuall...

Descripción completa

Detalles Bibliográficos
Autores principales: Cava, Claudia, Bertoli, Gloria, Castiglioni, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989433/
https://www.ncbi.nlm.nih.gov/pubmed/29871693
http://dx.doi.org/10.1186/s12967-018-1535-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989433/
https://www.ncbi.nlm.nih.gov/pubmed/29871693
http://dx.doi.org/10.1186/s12967-018-1535-2

Ejemplares similares